Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

17 18 Next >

Cancer-Focused Imago BioSciences Shares Soar After Merck Deal ↗

November 21, 2022

Via Benzinga

Expert Ratings for Seagen ↗

November 21, 2022

Via Benzinga

Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

November 15, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 15, 2022 – USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech...

Via FinancialNewsMedia

Topics Death

Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles ↗

November 10, 2022

Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen.

Via Investor's Business Daily

Seagen Inc. (SGEN) Q3 2022 Earnings Call Transcript ↗

October 28, 2022

SGEN earnings call for the period ending September 30, 2022.

Via The Motley Fool

What 8 Analyst Ratings Have To Say About Seagen ↗

October 13, 2022

Within the last quarter, Seagen (NASDAQ:SGEN) has observed the following analyst ratings:

Via Benzinga

With Meaningful Upside, This Cancer Stock Earns Analyst Upgrade ↗

October 11, 2022

Via Benzinga

Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma

November 10, 2022

From Seagen Inc.

Via Business Wire

Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting

November 10, 2022

From Seagen Inc.

Via Business Wire

Seagen Appoints Sandra M. Swain, M.D., to Board of Directors

November 10, 2022

From Seagen Inc.

Via Business Wire

Seagen Names David R. Epstein as Chief Executive Officer and Director

November 10, 2022

From Seagen Inc.

Via Business Wire

Seattle Genetics's Return On Capital Employed Insights ↗

November 02, 2022

Benzinga Pro data, Seattle Genetics (NASDAQ:SGEN) reported Q3 sales of $510.30 million. Earnings fell to a loss of $190.82 million, resulting in a 41.53% decrease from last quarter.

Via Benzinga

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗

November 01, 2022

October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...

Via Benzinga

Honeywell International, Seagen, New York Community Bancorp And This Transportation Company Featured On CNBC's Final Trade ↗

November 01, 2022

On CNBC’s “Halftime Report Final Trades,” Joseph Terranova of Virtus Investment Partners recommended buying shares of Seagen Inc. (NASDAQ: SGEN).

Via Benzinga

Seagen Reports Third Quarter 2022 Financial Results

October 27, 2022

From Seagen Inc.

Via Business Wire

Earnings Scheduled For October 27, 2022 ↗

October 27, 2022

Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.

Via Benzinga

What 9 Analyst Ratings Have To Say About Seagen ↗

October 24, 2022

Over the past 3 months, 9 analysts have published their opinion on Seagen (NASDAQ:SGEN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's...

Via Benzinga

A Bearish Sign Appears On Seagen's Chart ↗

October 24, 2022

If history is any guide, there may be trouble ahead for shares of Seagen (NASDAQ:SGEN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Via Benzinga

Morgan Stanley Maintains Overweight Rating for Seagen: Here's What You Need To Know ↗

October 13, 2022

Morgan Stanley has decided to maintain its Overweight rating of Seagen (NASDAQ:SGEN) and lower its price target from $181.00 to $170.00. Shares of Seagen are trading up 0.36% over the last 24 hours, at...

Via Benzinga

Is Seagen Stock a Buy Now? ↗

October 12, 2022

It's growing faster than competitors, but headwinds might soon bog it down.

Via The Motley Fool

BMO Capital Upgrades Seagen: Here's What You Need To Know ↗

October 11, 2022

BMO Capital upgraded its rating of Seagen (NASDAQ:SGEN) to Outperform with a price target of $178.00, changing its price target from $177.00 to $178.00. Shares of Seagen are trading up 2.5% over the...

Via Benzinga

Biohaven Ltd. Surges 7.6%: Is This An Indication Of Further Gains? ↗

October 07, 2022

Biohaven Ltd. shares ended the last trading session 7.6% higher at $13.18. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 ↗

October 11, 2022

Upgrades

Via Benzinga

Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027

October 06, 2022

Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing...

Via FinancialNewsMedia

Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial Results on October 27, 2022

October 06, 2022

From Seagen Inc.

Via Business Wire

Week In Review: YishengBio To List On NASDAQ Via SPAC Merger At An $834 Million Value ↗

October 01, 2022

Beijing YishengBio will merge with a SPAC vehicle, Summit Healthcare Acquisition, to list on the NASDAQ Exchange at a pre-money equity value of $834 million. The merger is expected to provide up to...

Via Talk Markets

'Right Now, You've Still Got To Avoid The Stock,' Jim Cramer Says About This Aerospace Company ↗

September 30, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE: SHW) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock.

Via Benzinga

Joe Terranova Is Buying This Stock: Wednesday's CNBC 'Fast Money' Final Trades ↗

September 28, 2022

CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned. The information is collected and refined...

Via Benzinga

Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment ↗

September 27, 2022

Via Benzinga

Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)

September 27, 2022

From Seagen Inc.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.